Huang J, Ang L, Liu M-Q, Hu H-G, Wang J, Zou Q, Zhao Y, Zheng L, Zhao M, Wu Z-S
Department of Pathology, The Second People's Hospital of Hefei, Hefei, Anhui, P.R. China.
Eur Rev Med Pharmacol Sci. 2014;18(18):2662-9.
This study aimed to investigate the levels of matrix metalloproteinases (MMP)-2, MMP-9 and Twist in tumor tissue and serum from 46 cases of breast cancer patients and 31 cases of benign breast diseases patients by immunohistochemical staining and enzyme-linked immunosorbent assay, respectively. The association of gelatinase and Twist expression with clinicopathological factors was also analyzed in the present study.
The studied population consisted of 46 breast cancer patients and 31 benign breast disease patients. Serum concentrations of MMP-2, MMP-9 and Twist were measured by using human enzyme-linked immunosorbent assay. The protein expression of Twist, MMP-2 and MMP-9 were determined by immunohistochemical.
The results show that the levels of MMP-2, MMP-9 and Twist expression were significantly increased in tissue and serum from breast cancer group, compared to the group of benign breast lesions diseases (p < 0.05). The pre-operative serum levels of MMP-2, MMP-9 and Twist were positively correlated with their expression in breast cancer tissues, respectively (p < 0.05). We, then, correlated serum and tissue levels of MMP-2, MMP-9 and Twist in breast cancer samples with patients' clinicopathologic characteristics. Compared to low expression, high serum and tissue levels of MMP-2 and Twist were associated with lymph node metastasis and higher TNM stage, high tissue MMP-9 levels were associated with lymph node metastasis and higher TNM stage, and high serum MMP-9 levels were associated with c-erbB-2 expression.
These data suggest that serum levels of MMP-2, MMP-9 and Twist could be as potential biomarkers for diagnosis and predicting metastasis of breast cancer.
本研究旨在分别通过免疫组织化学染色和酶联免疫吸附测定法,调查46例乳腺癌患者及31例乳腺良性疾病患者肿瘤组织和血清中基质金属蛋白酶(MMP)-2、MMP-9和Twist的水平。本研究还分析了明胶酶和Twist表达与临床病理因素的相关性。
研究人群包括46例乳腺癌患者和31例乳腺良性疾病患者。采用人酶联免疫吸附测定法测量血清中MMP-2、MMP-9和Twist的浓度。通过免疫组织化学法测定Twist、MMP-2和MMP-9的蛋白表达。
结果显示,与乳腺良性病变疾病组相比,乳腺癌组组织和血清中MMP-2、MMP-9和Twist的表达水平显著升高(p < 0.05)。术前血清中MMP-2、MMP-9和Twist的水平分别与其在乳腺癌组织中的表达呈正相关(p < 0.05)。然后,我们将乳腺癌样本中MMP-2、MMP-9和Twist的血清和组织水平与患者的临床病理特征进行关联分析。与低表达相比,血清和组织中MMP-2及Twist的高表达与淋巴结转移及更高的TNM分期相关,组织中MMP-9的高表达与淋巴结转移及更高的TNM分期相关,血清中MMP-9的高表达与c-erbB-2表达相关。
这些数据表明,血清中MMP-2、MMP-9和Twist的水平可能作为乳腺癌诊断和预测转移的潜在生物标志物。